This company listing is no longer active
0IVZ Stock Overview
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 2/6 |
Dividends | 0/6 |
Global Blood Therapeutics, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$68.48 |
52 Week High | US$72.00 |
52 Week Low | US$21.75 |
Beta | 0.46 |
1 Month Change | 0.94% |
3 Month Change | 126.38% |
1 Year Change | 163.74% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 13.85% |
Recent News & Updates
Recent updates
Shareholder Returns
0IVZ | GB Biotechs | GB Market | |
---|---|---|---|
7D | 0.9% | -0.9% | -0.01% |
1Y | 163.7% | -29.6% | 0.8% |
Return vs Industry: 0IVZ exceeded the UK Biotechs industry which returned -38.4% over the past year.
Return vs Market: 0IVZ exceeded the UK Market which returned -12.6% over the past year.
Price Volatility
0IVZ volatility | |
---|---|
0IVZ Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 7.2% |
Market Average Movement | 4.9% |
10% most volatile stocks in GB Market | 11.4% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0IVZ's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 0IVZ's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 457 | Ted Love | https://www.gbt.com |
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase II a clinical trial of adolescent and pediatric patients with SCD.
Global Blood Therapeutics, Inc. Fundamentals Summary
0IVZ fundamental statistics | |
---|---|
Market cap | US$4.62b |
Earnings (TTM) | -US$322.46m |
Revenue (TTM) | US$234.86m |
19.7x
P/S Ratio-14.3x
P/E RatioIs 0IVZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
0IVZ income statement (TTM) | |
---|---|
Revenue | US$234.86m |
Cost of Revenue | US$4.45m |
Gross Profit | US$230.41m |
Other Expenses | US$552.87m |
Earnings | -US$322.46m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -4.78 |
Gross Margin | 98.10% |
Net Profit Margin | -137.30% |
Debt/Equity Ratio | 491.7% |
How did 0IVZ perform over the long term?
See historical performance and comparison